Showing results (741-750 of 768) with videos related to
Sort By:
Pageof 77
Molecular Cancer Therapeutics|April 1, 2015
Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast CancerOlga Karginova, Marni B Siegel, Amanda E D Van Swearingen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2020
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular CarcinomaRichard S Finn, Masafumi Ikeda, Andrew X Zhu, et al.Liver Cancer|October 30, 2023
Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer Term Follow-Up from the Phase 3 KEYNOTE-240 TrialPhilippe Merle, Masatoshi Kudo, Julien Edeline, et al.JHEP Reports : Innovation in Hepatology|June 9, 2025
Second-line pembrolizumab for advanced HCC: Meta-analysis of the phase III KEYNOTE-240 and KEYNOTE-394 studiesRichard S Finn, Kangsheng Gu, Xi Chen, et al.Cancer|November 24, 2020
Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240Baek-Yeol Ryoo, Philippe Merle, Amit S Kulkarni, et al.The Lancet. Oncology|June 8, 2018
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trialAndrew X Zhu, Richard S Finn, Julien Edeline, et al.European Journal of Cancer (Oxford, England : 1990)|April 1, 2022
Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenibMasatoshi Kudo, Richard S Finn, Julien Edeline, et al.Lancet (London, England)|April 19, 2023
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trialRobin Kate Kelley, Makoto Ueno, Changhoon Yoo, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2019
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III TrialRichard S Finn, Baek-Yeol Ryoo, Philippe Merle, et al.Proceedings of the National Academy of Sciences of the United States of America|March 17, 2015
Computational protein design enables a novel one-carbon assimilation pathwayJustin B Siegel, Amanda Lee Smith, Sean Poust, et al.Pageof 77